ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

desloratadine

Also written as “Desloratadine”, “Desloratadine 5 mg” and “Desloratadine 5 mg (Clarinex)”.

Its studies are mostly in Rhinitis, Allergic, Seasonal · Rhinitis, Allergic · Urticaria · Hypersensitivity · Chronic Urticaria, led by 6 companies.

Drug pageDesloratadine: every studyMany companies study it; this page follows only the 39 they lead. All 55 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 4, 200639 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Organonits history only270 open or runningphase 4since Apr 4, 2006Apr 4, 2006none ahead
Dr. Reddy's Laboratories60 open or runningphase 1since Mar 11, 2011Mar 11, 2011none ahead
EMSits history only30 open or runningphase 3since Feb 6, 2012Feb 6, 2012none ahead
Ache Laboratorios Farmaceuticosits history only10 open or runningphase 3since Mar 8, 2016Mar 8, 2016none ahead
Eurofarma Laboratoriosits history only10 open or runningphase 3since Dec 13, 2021Dec 13, 2021none ahead
Laboratorios Silanes S.A. de C.V.its history only10 open or runningphase 3since Apr 1, 2025Apr 1, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 11, 2011First studies: 2 phase 1 studiesFirst studyNCT01314352, NCT01314339
  2. Jun 10, 2011Phase 1 study in HealthyNCT01373138 · 34 enrolled · Canada
  3. Sep 27, 2011Phase 1 study in HealthyNCT01506791 · 44 enrolled · United States
  4. Jan 5, 20122 phase 1 studies in HealthyNCT01506050, NCT01506037

TargetBeta

HRH1 →read by rule
“Histamine H1 receptor antagonist”ChEMBL 37, by rule

Other programs on HRH1

ProgramCompanyFurthest phaseStudies
fexofenadineruleSanofiphase 438
bilastinerulefaes-farma-s-aphase 419
DiphenhydramineruleJohnson & Johnsonphase 416

Studies

All 6 Dr. Reddy's Laboratories leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01506050Healthy · United States1Completed35
NCT01506037Healthy · United States1Completed36
NCT01506791Healthy · United States1Completed44
NCT01373138Healthy · Canada1Completed34
NCT01314352Lecithin Cholesterol Acyltransferase Deficiency · United States1CompletedDec 200528
NCT01314339Fasting · United States1CompletedDec 200528

How it is read

Names in the registry

  • “Desloratadine”, 12 entries
  • “desloratadine”, 11 entries
  • “Desloratadine 5 mg”, 3 entries
  • “Desloratadine 5 mg (Clarinex)”, 3 entries
  • “Desloratadine + Prednisolone”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.